SIRION Biotech and Denali Therapeutics Join Forces to Develop Gene Therapies for Diseases of the Central Nervous System
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced…
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced…
The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with He…
SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene…
Virale Vektoren sind eine neue Klasse biologischer Arzneimittel zur Heilung von Krankheiten, die auf einer bekannten Feh…
Viral vectors are a new class of biologics that help treat diseases caused by defective gene function / proteins ("gene…
SIRION Biotech GmbH enables its customers to advance the field of gene therapy through multiple proprietary viral vector…
SIRION Biotech ermöglicht ihren Kunden Fortschritte in der Gentherapie mithilfe mehrerer Plattformen zu viralen Vektoren…
SIRION Biotech announced today it is now providing viral vectors for preclinical use to be expressed in CEVEC's CAP®-Tec…
SIRION Biotech gab heute bekannt, daß es seine viralen Vektoren für präklinischen Einsatz jetzt auch mithilfe CEVEC's CA…
SIRION Biotech announced today its novel lentivirus portfolio for the most sophisticated in vitro applications. Besides…